Drug Treatment for Diabetic Foot.

Denosumab for diabetic charcot neuroarthropathy in people with chronic kidney Disease:a randomized controlled study. - DECK

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031379

Enrollment

Registered

2021-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Denosumab: Injection 60mg subcutaneously. once only Control Intervention1: Placebo: Equal volume normal saline(subcutaneously) once only.

Eligibility

Inclusion criteria

Inclusion criteria: Participants with any form of diabetes, age more than 18 years and with nephropathy defined as eGFR 300 mg and/or end stage kidney disease on maintenance dialysis or post renal transplant for DKD will be included.

Exclusion criteria

Exclusion criteria: Patients with active foot ulcer or who have received denosumab or any other anti-resorptive therapy in the prior six months, harboring an active malignancy, pregnant or lactating women will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the median time to clinical remission of CN in the two groups and proportion of patients who achieved clinical remission within six months of intervention.Timepoint: 24 week	—

Secondary

Measure	Time frame
BTMs.Timepoint: 24 weeks.	—

Countries

India

Contacts

Public ContactAshu Rastogi

PGIMER

ashuendo@gmail.com9781001046

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026